HTX-011 FDA Approval Status
FDA Approved: No
Brand name: HTX-011
Generic name: bupivacaine and meloxicam
Company: Heron Therapeutics, Inc.
Treatment for: Postoperative Pain
HTX-011 (bupivacaine and meloxicam) is an investigational fixed-dose combination of the local anesthetic bupivacaine and the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in development for the management of postoperative pain.
Development Timeline for HTX-011
|Jun 29, 2020||Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain|
|Feb 19, 2020||Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain|
|Oct 28, 2019||Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain|
|Oct 1, 2019||Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain|
|May 1, 2019||Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain|
|Dec 31, 2018||FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management|
|Oct 31, 2018||Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management|
|Mar 19, 2018||Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials of HTX-011 in Bunionectomy and Hernia Repair|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.